When doctors discover a significant blockage in one of the heart's arteries, many people assume that a stent is the obvious next step. While this is often true during a heart attack or other acute coronary emergencies, the decision is not always as straightforward for people with stable coronary artery disease.
For years,
coronary stenting, also known as percutaneous coronary intervention (PCI), has
been widely used to relieve chest pain caused by narrowed arteries. The common
belief has been simple: restoring blood flow should reduce symptoms and improve
a patient's ability to exercise.
But is
opening a blocked artery always enough to make patients feel better?
This
question became the focus of one of the most influential studies in
interventional cardiology—the ORBITA trial, published in The Lancet in
2017. The study challenged long-held assumptions and changed how doctors think
about treating stable angina.
Question
that Challenged Conventional Practice: Why the ORBITA Trial Needed?
PCI is an
established, life-saving treatment for patients experiencing acute coronary
syndromes, such as a heart attack. However, its role in patients with stable
angina has remained a topic of debate for many years.
Before
ORBITA, clinical guidelines recommended PCI for patients whose symptoms
continued despite optimal medical therapy. Many physicians believed that
opening a narrowed artery would naturally improve symptoms by restoring blood
flow.
However,
one important question had never been answered.
Could the
improvement patients experienced after stenting be partly influenced by the
placebo effect?
Until
ORBITA, no clinical trial had compared PCI with a sham procedure while keeping
both patients and outcome assessors blinded. This left uncertainty about how
much of the symptom relief was truly due to the procedure itself.
Inside the ORBITA Trial: How Did
Researchers Test This?
To answer
this question, researchers designed ORBITA as the first double-blind,
randomized, placebo-controlled trial evaluating PCI in patients with stable
single-vessel coronary artery disease.
The study
enrolled 200 patients with severe narrowing (at least 70% stenosis) in a single
coronary artery. Patients with multivessel coronary artery disease were
excluded to ensure a more uniform study population.
Before
randomization, every participant underwent six weeks of intensive medical
therapy to optimize antianginal medications. Researchers also evaluated
symptoms, exercise capacity, heart function during stress, and quality of life.
Patients
were then randomly assigned to receive either:
● PCI with a drug-eluting stent, or
● A carefully designed placebo (sham) procedure.
Neither the
patients nor the clinicians assessing the outcomes knew which treatment had
been performed. This blinded design helped isolate the true effect of PCI from
any placebo response.
The primary
goal was to determine whether PCI improved treadmill exercise time six weeks
after treatment.
What
the ORBITA Trial Revealed
The
findings that changed the conversation and the results surprised many
cardiologists.
Although
patients who underwent PCI showed a greater increase in exercise time than
those who received the placebo procedure, the difference was not statistically
significant.
The PCI
group improved exercise time by 28.4 seconds, while the placebo group improved
by 11.8 seconds. The average difference between the two groups was 16.6
seconds, which fell short of the trial's predefined threshold for clinical
significance.
Researchers
also found that:
● Both groups reported similar improvements in
angina symptoms.
● Quality of life improved in both groups.
● Canadian Cardiovascular Society (CCS) angina
class improved similarly regardless of treatment.
These
findings suggested that some of the symptom improvement traditionally
attributed to PCI might also be influenced by patient expectations and the
placebo effect.
Looking
Beyond Symptom Relief
PCI still
produced clear physiological benefits! While the improvement in symptoms was
smaller than expected, the procedure clearly improved heart physiology.
Compared
with the placebo group, PCI significantly reduced ischemia and improved blood
flow through the treated artery.
Researchers
observed:
● Significant improvement in fractional flow
reserve (FFR) and instantaneous wave-free ratio (iFR), confirming better
coronary blood flow.
● Reduced ischemia on stress echocardiography.
● Improved wall motion stress index after
stenting.
These
findings showed that PCI effectively corrected the blockage from a
physiological standpoint, even though this did not translate into a major
short-term improvement in exercise capacity.
Understanding
the Bigger Picture: What Do These Results Mean?
Lead investigator
Dr. Rasha Al-Lamee of Imperial College London concluded that PCI clearly
improved blood flow and objective measures of ischemia. However, it did not
produce significantly greater symptom relief than the placebo procedure over
six weeks.
Rather than
suggesting that stents are ineffective, ORBITA highlighted an important
distinction between improving coronary blood flow and improving how patients
feel.
For
patients with stable coronary artery disease, symptom relief appears to be
influenced by multiple factors, including the mechanical benefit of restoring
blood flow, the effectiveness of medical therapy, and psychological factors
such as patient expectations.
This
finding reinforced the importance of treating the patient rather than focusing
solely on the appearance of a coronary blockage.
Limitations
of the ORBITA Trial
Like any
clinical trial, ORBITA had limitations that should be considered before
applying its findings broadly.
● The follow-up period lasted only six weeks.
● The study included just 200 patients.
● Only patients with single-vessel disease were
enrolled, limiting applicability to more complex coronary disease.
● The trial was designed to evaluate symptom
improvement rather than long-term outcomes such as heart attacks or survival.
Researchers
later addressed some of these questions in ORBITA-2, published in 2023. Unlike
the original study, ORBITA-2 evaluated PCI without background antianginal
medication and found that PCI significantly reduced angina symptoms. Together,
the two studies suggest that the benefit of PCI depends not only on the
procedure itself but also on the clinical setting and the patient's medical
therapy.
What
Does This Mean for Patients Today?
The ORBITA
trial did not eliminate the role of PCI. Instead, it helped refine when the
procedure is most appropriate.
Current
evidence supports:
● Guideline-directed medical therapy as the
first-line treatment for stable angina.
● PCI for patients who continue to experience
symptoms despite optimized medication.
● Functional assessments such as FFR or iFR to
determine whether a blockage is causing significant ischemia before proceeding
with revascularization.
● Shared decision-making, with realistic
discussions about the expected benefits of elective PCI.
Non-invasive
therapies may also play an important role for selected patients. At Heal YourHeart, Enhanced External Counterpulsation (EECP) is offered as a treatment
option for patients with chronic stable angina who remain symptomatic despite
optimal medical therapy or are not suitable candidates for revascularization.
By promoting coronary collateral circulation and reducing cardiac workload,
EECP complements guideline-directed medical management in appropriately
selected patients.
Conclusion
The ORBITA
trial did not show that stents are unnecessary—it showed that not every stable
coronary blockage automatically requires one. While PCI clearly improves blood
flow and reduces ischemia, its impact on symptom relief depends on the
individual patient, the severity of symptoms, and the effectiveness of medical
therapy.
The study
reinforced an important shift in modern cardiology: treatment decisions should
not rely solely on how severe a blockage looks on an angiogram. Instead, they
should combine functional testing, optimized medical therapy, and a careful
assessment of the patient's symptoms and overall clinical condition.
For
patients with stable angina, the goal is not simply to open an artery but to
choose the treatment that offers the greatest meaningful benefit. In many
cases, that may be PCI. In others, medications or non-invasive therapies such
as EECP may provide effective symptom relief. Ultimately, the right treatment
is one that is guided by evidence and tailored to the individual patient.
For More Details About EECP Call : 9003070065 / 9003070064
• ORBITA Trial (BMJ): https://www.bmj.com/content/359/bmj.j5076 • Related article: https://share.google/joJzFwvfA7yvwba74
Comments
Post a Comment